[1] Perrault A, Wolfson C, Egan M, Rockwood K, Hogan DB. Prognostic factors for functional independence in older adults with mild dementia: results from the Canadian study of health and aging. Alzheimer Disease & Associated Disorders. 2002 Oct 1;16(4):239-47.
[2] Holmes C, Lovestone S. Long‐term cognitive and functional decline in late onset Alzheimer's disease: therapeutic implications. Age and ageing. 2003 Mar 1;32(2):200-4.
[3] Corey-Bloom J, Fleisher AS. The natural history of Alzheimer’s disease. Dementia. 2000;34:405-15.
[4] Holmes C. Genotype and phenotype in Alzheimer's disease. The British Journal of Psychiatry. 2002 Feb;180(2):131-4.
[5] Lo MT, Kauppi K, Fan CC, Sanyal N, Reas ET, Sundar VS, Lee WC, Desikan RS, McEvoy LK, Chen CH, Alzheimer's Disease Genetics Consortium. Identification of genetic heterogeneity of Alzheimer's disease across age. Neurobiology of aging. 2019 Dec 1;84:243-e1.
[6] Holmes C, Ballard C, Lehmann D, Smith AD, Beaumont H, Day IN, Khan MN, Lovestone S, McCulley M, Morris CM, Munoz DG. Rate of progression of cognitive decline in Alzheimer’s disease: effect of butyrylcholinesterase K gene variation. Journal of Neurology, Neurosurgery & Psychiatry. 2005 May 1;76(5):640-3.
[7] Fan J, Tao W, Li X, Li H, Zhang J, Wei D, Chen Y, Zhang Z. The Contribution of Genetic Factors to Cognitive Impairment and Dementia: Apolipoprotein E Gene, Gene Interactions, and Polygenic Risk. International journal of molecular sciences. 2019 Jan;20(5):1177.
[8] Euesden J, Gowrisankar S, Qu AX, Jean PS, Hughes AR, Pulford DJ. Cognitive Decline in Alzheimer’s Disease: Limited Clinical Utility for GWAS or Polygenic Risk Scores in a Clinical Trial Setting. Genes. 2020 May;11(5):501.
[9] Reitz C, Mayeux R. Use of genetic variation as biomarkers for mild cognitive impairment and progression of mild cognitive impairment to dementia. Journal of Alzheimer's Disease. 2010 Jan 1;19(1):229-51.
[10] Bäckman L, Jones S, Small BJ, Agüero-Torres H, Fratiglioni L. Rate of cognitive decline in preclinical Alzheimer's disease: the role of comorbidity. The Journals of Gerontology Series B: Psychological Sciences and Social Sciences. 2003 Jul 1;58(4):P228-36.
[11] Lee E, Giovanello KS, Saykin AJ, Xie F, Kong D, Wang Y, Yang L, Ibrahim JG, Doraiswamy PM, Zhu H, Alzheimer's Disease Neuroimaging Initiative. Single-nucleotide polymorphisms are associated with cognitive decline at Alzheimer's disease conversion within mild cognitive impairment patients. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. 2017 Jan 1;8:86-95.
[12] Kunkle BW, Grenier-Boley B, Sims R, Bis JC, Damotte V, Naj AC, Boland A, Vronskaya M, Van Der Lee SJ, Amlie-Wolf A, Bellenguez C. Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nature genetics. 2019 Mar;51(3):414-30.
[13] Savage JE, Jansen PR, Stringer S, Watanabe K, Bryois J, De Leeuw CA, Nagel M, Awasthi S, Barr PB, Coleman JR, Grasby KL. Genome-wide association meta-analysis in 269,867 individuals identifies new genetic and functional links to intelligence. Nature genetics. 2018 Jul;50(7):912-9.
[14] Lee JJ, Wedow R, Okbay A, Kong E, Maghzian O, Zacher M, Nguyen-Viet TA, Bowers P, Sidorenko J, Linnér RK, Fontana MA. Gene discovery and polygenic prediction from a 1.1-million-person GWAS of educational attainment. Nature genetics. 2018 Aug;50(8):1112.
[15] Torkamani A, Wineinger NE, Topol EJ. The personal and clinical utility of polygenic risk scores. Nature Reviews Genetics. 2018 Sep;19(9):581-90.
[16] Chasioti D, Yan J, Nho K, Saykin AJ. Progress in polygenic composite scores in Alzheimer’s and other complex diseases. Trends in Genetics. 2019 May 1;35(5):371-82.
[17] Martin AR, Daly MJ, Robinson EB, Hyman SE, Neale BM. Predicting polygenic risk of psychiatric disorders. Biological psychiatry. 2019 Jul 15;86(2):97-109.
[18] Mattsson N, Insel PS, Palmqvist S, Stomrud E, Van Westen D, Minthon L, Zetterberg H, Blennow K, Hansson O. Increased amyloidogenic APP processing in APOE ɛ4-negative individuals with cerebral β-amyloidosis. Nature communications. 2016 Mar 7;7(1):1-7.
[19] Ossenkoppele R, Rabinovici GD, Smith R, Cho H, Schöll M, Strandberg O, Palmqvist S, Mattsson N, Janelidze S, Santillo A, Ohlsson T. Discriminative accuracy of [18F] flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders. Jama. 2018 Sep 18;320(11):1151-62.
[20] Jack Jr CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J, Liu E. NIA‐AA research framework: toward a biological definition of Alzheimer's disease. Alzheimer's & Dementia. 2018 Apr;14(4):535-62.
[21] Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. Journal of psychiatric research. 1975 Nov 1;12(3):189-98.
[22] Anderson CA, Pettersson FH, Clarke GM, Cardon LR, Morris AP, Zondervan KT. Data quality control in genetic case-control association studies. Nature protocols. 2010 Sep;5(9):1564-73.
[23] Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience. 2015 Dec 1;4(1):s13742-015.
[24] Janelidze S, Zetterberg H, Mattsson N, Palmqvist S, Vanderstichele H, Lindberg O, van Westen D, Stomrud E, Minthon L, Blennow K, Swedish BioFinder Study Group. CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease. Annals of clinical and translational neurology. 2016 Mar;3(3):154-65.
[25] Pomaznoy M, Ha B, Peters B. GOnet: a tool for interactive Gene Ontology analysis. Bmc Bioinformatics. 2018 Dec;19(1):470.
[26] Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, Simonovic M, Doncheva NT, Morris JH, Bork P, Jensen LJ. STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic acids research. 2019 Jan 8;47(D1):D607-13.
[27] Jassal B, Matthews L, Viteri G, Gong C, Lorente P, Fabregat A, Sidiropoulos K, Cook J, Gillespie M, Haw R, Loney F. The reactome pathway knowledgebase. Nucleic acids research. 2020 Jan 8;48(D1):D498-503.
[28] Insel PS, Hansson O, Mattsson-Carlgren N. Association Between Apolipoprotein E ε2 vs ε4, Age, and β-Amyloid in Adults Without Cognitive Impairment. JAMA neurology.
[29] Ge T, Sabuncu MR, Smoller JW, Sperling RA, Mormino EC, Alzheimer's Disease Neuroimaging Initiative. Dissociable influences of APOE ε4 and polygenic risk of AD dementia on amyloid and cognition. Neurology. 2018 May 1;90(18):e1605-12.
[30] Porter T, Burnham SC, Milicic L, Savage G, Maruff P, Lim YY, Li QX, Ames D, Masters CL, Rainey-Smith S, Rowe CC. Utility of an Alzheimer’s Disease risk-weighted polygenic risk score for predicting rates of cognitive decline in preclinical alzheimer’s disease: a prospective longitudinal study. Journal of Alzheimer's Disease. 2018 Jan 1;66(3):1193-211.
[31] Porter T, Burnham SC, Savage G, Lim YY, Maruff P, Milicic L, Peretti M, Ames D, Masters CL, Martins RN, Rainey-Smith S. A polygenic risk score derived from episodic memory weighted genetic variants is associated with cognitive decline in preclinical Alzheimer’s disease. Frontiers in aging neuroscience. 2018 Dec 19;10:423.
[32] Tan CH, Hyman BT, Tan JJ, Hess CP, Dillon WP, Schellenberg GD, Besser LM, Kukull WA, Kauppi K, McEvoy LK, Andreassen OA. Polygenic hazard scores in preclinical Alzheimer disease. Annals of neurology. 2017 Sep;82(3):484-8.
[33] Logue MW, Panizzon MS, Elman JA, Gillespie NA, Hatton SN, Gustavson DE, Andreassen OA, Dale AM, Franz CE, Lyons MJ, Neale MC. Use of an Alzheimer’s disease polygenic risk score to identify mild cognitive impairment in adults in their 50s. Molecular psychiatry. 2019 Mar;24(3):421-30.
[34] Vemuri P, Knopman DS, Lesnick TG, Przybelski SA, Mielke MM, Graff-Radford J, Murray ME, Roberts RO, Vassilaki M, Lowe VJ, Machulda MM. Evaluation of amyloid protective factors and Alzheimer disease neurodegeneration protective factors in elderly individuals. JAMA neurology. 2017 Jun 1;74(6):718-26.
[35] Vemuri P, Lesnick TG, Przybelski SA, Machulda M, Knopman DS, Mielke MM, Roberts RO, Geda YE, Rocca WA, Petersen RC, Jack CR. Association of lifetime intellectual enrichment with cognitive decline in the older population. JAMA neurology. 2014 Aug 1;71(8):1017-24.
[36] Vemuri P, Lesnick TG, Przybelski SA, Knopman DS, Machulda M, Lowe VJ, Mielke MM, Roberts RO, Gunter JL, Senjem ML, Geda YE. Effect of intellectual enrichment on AD biomarker trajectories: longitudinal imaging study. Neurology. 2016 Mar 22;86(12):1128-35.
[37] Osler M, Christensen GT, Garde E, Mortensen EL, Christensen K. Cognitive ability in young adulthood and risk of dementia in a cohort of Danish men, brothers, and twins. Alzheimer's & Dementia. 2017 Dec 1;13(12):1355-63.
[38] Kauppi K, Rönnlund M, Adolfsson AN, Pudas S, Adolfsson R. Effects of polygenic risk for Alzheimer’s disease on rate of cognitive decline in normal aging. Translational psychiatry. 2020 Jul 24;10(1):1-8.
[39] Rawlings AM, Sharrett AR, Mosley TH, Wong DF, Knopman DS, Gottesman RF. Cognitive reserve in midlife is not associated with amyloid-β deposition in late-life. Journal of Alzheimer's Disease. 2019 Jan 1;68(2):517-21.
[40] Jack Jr CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. The Lancet Neurology. 2010 Jan 1;9(1):119-28.
[41] Insel PS, Ossenkoppele R, Gessert D, Jagust W, Landau S, Hansson O, Weiner MW, Mattsson N, Alzheimer's Disease Neuroimaging Initiative. Time to amyloid positivity and preclinical changes in brain metabolism, atrophy, and cognition: evidence for emerging amyloid pathology in Alzheimer's disease. Frontiers in neuroscience. 2017 May 17;11:281.
[42] Insel PS, Mattsson N, Mackin RS, Schöll M, Nosheny RL, Tosun D, Donohue MC, Aisen PS, Jagust WJ, Weiner MW, Alzheimer's Disease Neuroimaging Initiative. Accelerating rates of cognitive decline and imaging markers associated with β-amyloid pathology. Neurology. 2016 May 17;86(20):1887-96.
[43] Ebert MS, Sharp PA. Emerging roles for natural microRNA sponges. Current Biology. 2010 Oct 12;20(19):R858-61.
[44] Singh D, Singh PK, Chaudhary S, Mehla K, Kumar S. Exome sequencing and advances in crop improvement. Advances in genetics. 2012 Jan 1;79:87-121.
[45] Wu F, Yao PJ. Clathrin-mediated endocytosis and Alzheimer's disease: an update. Ageing research reviews. 2009 Jul 1;8(3):147-9.
[46] Alsaqati M, Thomas RS, Kidd EJ. Proteins involved in endocytosis are upregulated by ageing in the normal human brain: Implications for the development of alzheimer’s disease. The Journals of Gerontology: Series A. 2018 Mar 2;73(3):289-98.
[47] He F, Balling R. The role of regulatory T cells in neurodegenerative diseases. Wiley Interdisciplinary Reviews: Systems Biology and Medicine. 2013 Mar;5(2):153-80.
[48] Ruano D, Abecasis GR, Glaser B, Lips ES, Cornelisse LN, de Jong AP, Evans DM, Smith GD, Timpson NJ, Smit AB, Heutink P. Functional gene group analysis reveals a role of synaptic heterotrimeric G proteins in cognitive ability. The American Journal of Human Genetics. 2010 Feb 12;86(2):113-25.
[49] Pavlowsky A, Chelly J, Billuart P. Emerging major synaptic signaling pathways involved in intellectual disability. Molecular psychiatry. 2012 Jul;17(7):682-93.
[50] Taneja P, Ogier M, Brooks-Harris G, Schmid DA, Katz DM, Nelson SB. Pathophysiology of locus ceruleus neurons in a mouse model of Rett syndrome. Journal of Neuroscience. 2009 Sep 30;29(39):12187-95.